**Research progress of PD-1/PD-L1 and IL-17A on Lymphomas**

**Abstract**

Li Yang, Xin Xu

Guangzhou First People's Hospital

e-mail:498680671@qq.com

In recent years, tumor microenvironment has become the focus of immunotherapy point in lymphoma. Programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) signaling pathway is one of important mechanism of cancer immunomodulatory, and its abnormal activation in tumor microenvironment shows that PD-1/PD-L1 pathway may take part in the regulation of tumor immune escape. IL-17A is a pro-inflammatory cytokine which plays a crucial role in lymphoma cancer microenvironment and it act divided roles in both tumor growth and cancer elimination, so IL-17A has also become a hot topic in cancer immunotherapy. In previous study, papers have reported that IL-17A up-regulated the expression of PD-L1 in cancers or in autoimmune diseases, while fewer research in lymphoma. We guess that whether there is an interaction or relationship between PD-1/PD-L1 pathway and IL-17A in lymphoma. Therefore, we aimed to review the progress of PD-1/PD-L1 pathway and IL-17A on lymphomas in this paper. We hope the better understanding of PD-1/PDL1 pathway and IL-17A can bring us an inspiration to find novel lymphomas therapeutic directions in future.

**Key words:** PD-1/PD-L1, IL-17A, Lymphoma, tumor microenvironment, immune

**Introduction**

Lymphoma is one of hematological malignancy which is prevalent in world. In recent years, some types of lymphomas have become treatable, while relapsed or refractory lymphomas remain ordinary and challenging, which push us to seek new treatments for lymphomas.

PD-1 is expressed on the activated T cells, monocytes, dendritic cells (DCs), natural killer (NK) and B lymphocytes, macrophages[1], especially, over-expressed on the tumor-specific T cells. it is expressed on tumor-specific T cells highly[2]. Normal antigen-presenting cells, macrophages, and dendritic cells express PD-1 ligands that combine with PD-1 receptors on the activated T cells. As PD-1 is just expressed on the surface of activated T lymphocytes, instead of resting T cells, consequently, it usually used as an activation marker on T cells. When tumor cells over-express PD-L1, PD-1 interacts with PD-1 ligands, then the activation of PD-1/PD-L1 signal pathway can suppresses T-cell function, reducing the T-cell to a dysfunctional state called exhaustion, leading to tumor immune escape and being highly refractory to conventional chemotherapy.

In some previous studies, it has reported that the expression of PD-L1 predicts a worse outcome and is related to poor survival rate in malignant lymphoma patients[3-6].

Cancer cells capable of evading immune-surveillance via PD-1/PD-L1 signal pathway:

 by 1) suppressing TIL activation and inducing cells apoptosis, 2) suppressing the production of CTL granular enzyme and perforin, 3) inducing the secretion of inflammatory cytokines, such as IFN-γ, TNF-α, IL-2 and enhancing the secretion of the immune inhibitory cytokine IL-10, 4) making T cell cycle stagnating, and leading cells accumulating in G0/G1 phase, 5) promoting tumor cell epithelialization, tumor invasion and metastasis[7]. Based on the molecular mechanism of the PD-1/PD-L1 signaling pathway, as a target for immunotherapy, an amount of anti-PD-1/PD-L1 antibodies are applied for curing cancers.

Interleukin-17 (IL-17; also known as IL-17A, originally termed CTLA8) is produced by Th17 cells, γδT cells, Natural Killer cells (NK cells), and CD8 T cells in the cancer microenvironment [8]. IL-17 is the prototypical member of the IL-17 family of pro-inflammatory cytokines and it is the extensively researched member in the IL-17 family [9, 10], which plays a vital role in tissue inflammation and the pathogenesis of many autoimmune diseases[11]. Despite IL-17A is widely studied in inflammation filed, but too little is known about their presence and role in cancers. In the past decades, many studies reported that IL-17A plays a dual role of tumor-promoting and tumor-suppressing in tumors, which may be related to complex tumor microenvironment, different tumor types, tumor development process, tumor etiology and tumor sensitivity to chemotherapeutic drugs. In this context, in recent years, IL-17A has also become one of the critical research hotspots in the field of lymphoma. While in lots of studies, IL-17A has been proved to promote tumor development in lymphoma, even leading to drug resistance[12-14]. In past study, it has reported that IL-17A could enhance the expression of PD-L1 in many tumors or in autoimmune diseases[15, 16], while little research in lymphoma. We guess that whether there is a relationship or interaction between PD-1/PD-L1 signal pathway and IL-17A in lymphoma [17, 18].

Therefore, we hope to provide a better understanding of PD-1/PDL1 and IL-17, which may provide new therapeutic ideas for the treatment of lymphoma in future.

**1.Expression and regulation of PD-1/PD-L1 in lymphoma**

Using the TCGA and GTEx databases, the study of Wei Zhang found that all B7 family members were highly expressed in diffuse large B cell lymphoma (DLBCL), beside B7-H5 ，showing that B7 family may play important roles in lymphoma immunization[19]. PD-L1 is not only expressed in DLBCL cancer cells, but also in cancer-infiltrating non-malignant cells. The study of David J. Andorsky show that PD-L1 is highly expressed in HL, ALCL and many poor prognosis DLBCLs originated from the ABC/non-GCB subtype, and it suppress the activity of Tumor-Associated T Cells[20]. The mechanism of PD-1/PD-L1 expression is complex. Various factors appear to influence the expressing of PD-1/PD-L1. And PD-1/PD-L1 expression played vital roles in propagation, immigration, evasion, drug-resistance and immune evasion of lymphoma.

* 1. **The activation of MEK／ERK、MAPK 、JAK/STAT pathway**

In anaplastic lymphoma kinase (ALK)+ anaplastic large cell lymphoma (ALCL) cells, the study found that the expression of PD-1 was inhibited by blocking the extracellular signal-regulated kinase (ERK) signal pathway and was upregulated by the augmentation of ERK activity, suggesting that the expression of PD-1 is regulated by ERK signal pathway in ALCL[21]. The overexpression of EBV-driven latent membrane proteins [LMP1 and LMP2] can enhance the expression of PD-L1 by activating the pro-proliferative NF-κb/MAPK signaling pathway[22]. And in infiltrating macrophages of lymphoma, it has been proved that the expression of PD-L1 and PD-L2 are induced by the IL-27/STAT3 signal pathway [23]. In another study, it shows that some chemotherapy drugs can upregulate PD-L1 expression in DLBCL cells partially through promoting the p-STAT3[24]. And in NKTL tumors, [Tammy Linlin Song](https://pubmed.ncbi.nlm.nih.gov/?term=Song+TL&cauthor_id=30054295) demonstrated that STAT3 activation confers high PD-L1 expression, which may enhance tumor immune evasion [25].

* 1. **A copy number alterations (CNAs) in chromosome 9p24.1**

The chromosomal abnormalities (including chromosomal amplification, polysomy, gain, or translocation) of 9p24.1, encoding PD-L1 and PD-L2 proteins and Janus kinase 2, have been reported to lead to the overexpression of PD-L1 and PD-L2[26]. Several previous studies have reported that the amplification of chromosome 9p24.1 enhances the abundance of both PD-L1 and their induction, JAK2, in the related diseases of nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma[27]. In addition, JAK2 signal pathway further strengthen the PD-L1 expression in cell lines with 9p24.1 amplification[28]. As such, the CNAs of 9p24.1 in lymphomas provides chance for examining the efficacy of immune checkpoint inhibitors targeting PD-1, which show to be effective in the treatment of relapsed/refractory lymphomas[29].

* 1. **Inducted by inflammatory factors such as IFN-γ、IL-27 and IL-1a**

In the study of Amy S. Duffield, the results demonstrated that beyond the known of IFN-γ in enhancing PD-L1 expression on DCs and monocytes, IL-27 and IL-1a can also increase the expression of PD-L1 on different immune cell subsets. [30].

**2. Application of PD-1/PD-L1 inhibitor in lymphoma**

In past, Lymphomas, especially non-Hodgkin lymphomas, the main approaches for treatment were surgery, radiotherapy and chemotherapy, while still there are a considerable proportion of lymphomas are progress/relapse after treatment, especially in aggressive lymphomas. DLBCL is the most general type of NHL in China, with strong heterogeneity. With the emergence of rituximab, we have achieved satisfactory results after the treatment of rituximab combined with chemotherapy, while there are still 30-40 % are refractory/relapsed. With the deepening research on tumor microenvironment and tumor immune regulation, immunotherapy has played a significant role and gradually been widely used in lymphoma, especially in refractory/relapsed lymphoma. Immunotherapy, such as chimeric antigen receptor (CAR) T cell therapy and therapeutic blockade of immune checkpoints, especially the PD-1/PD-L1 checkpoint inhibitor, is a breakthrough in therapy of malignant tumor[31, 32].

* 1. **Current PD-1/PD-L1 antibodies in lymphoma**

To date, many types of anti-PD-1 or anti-PD-L1 antibodies have been produced. The below is the finished clinical trials targeting on PD-1/PD-L1 in lymphoma: anti-PD-1 antibodies (Nivolumab[32, 33],Pembrolizumab[34-36],Geptanolimab[37],Camrelizumab[38], Tislelizumab[39],Sintilimab[40]) and anti-PD-L1 antibodies: (Avelumab[41], Atezolizumab[42], Durvalumab[43].)

In classical Hodgkin lymphoma (cHL), non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), nivolumab is indicated as a breakthrough therapy for treating relapsed/refractory (R/R) patients[44-47]. And Nivolumab has received approval for the treatment of relapsed or progressive classical Hodgkin lymphoma after autologous hematopoietic stem cell transplantation (HSCT). The FDA recently approved a monoclonal anti-PD-1 antibody (pembrolizumab) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma, or those who have relapsed after treatment[34]. A monoclonal anti-PD-1 antibody (sintilimab) is also used for the treatment of relapsed or refractory classical Hodgkin lymphoma (cHL) and extranodal natural killer (NK)/T-cell lymphoma (ENKTL) [48, 49].

* 1. **PD-1/PD-L1 antibodies combination with immunomodulatory drugs**

In multiple solid cancer types, the therapy of combining CTLA-4 and PD-1 blockers has shown remarkable clinical efficacies, and the discovery of CTLA-4 and PD-1 has made great effort to the development of cancer immunotherapy[50]. lots of clinical trials which testing the combination of PD-(L)1 or CTLA-4 antibodies with molecular mediators of these pathways are getting more and more popular[51]. For example, the results of Shi-Dong Ma’study indicated that the combination of PD-1 and CTLA-4 can increase the effect of cord blood T cells on EBV-induced lymphoma growth in a humanized mouse model of cord blood, suggesting that PD-1/CTLA-4 blockade may be helpful for the treatment of EBV-induced diseases in humans. What’s more, there is also evidence shows that the combined use of CTLA-4 antibodies and PD-1 antibodies shows greater clinical benefit than either antibody types alone [52]. There are many other clinicaltrials and pre-clinical tumor model experiments also being conducted to assess the effect of other checkpoint proteins combined with anti-PD-1/PD-L1 antibodies. It has expanded from CTLA-4 and PD-1 to include Tim-3, Lag-3 and most recently, TIGIT（PD-1/TIM-3、PD-1/LAG-3、PD-1/TIGIT）[53-58].

**2.3 PD-1/PD-L1 antibodies combination with chemotherapeutic drugs**

Chemotherapy is one of the main methods for tumor treatment, the way of killing tumor cells is by inducing DNA damage, cell-cyclearrest and making cells apoptosis eventually. The antitumor effect of chemotherapeutic drugs is affected by the immune status of patients, which provides us ideas for the development of combination regimens using PD-1/PD-L1 blockade with existed chemotherapeutics. One study demonstrated an important synergistic effect of PD-1 inhibitor and chemotherapeutic drugs like cisplatin, cytarabine, etoposide, oxaliplatin, and carboplatin in Diffuse large B-cell lymphoma (DLBCL). And there was no difference in cytotoxicity between the groups with or without PD-L1 inhibitor[59]. Besides, Stephen D Smith et al ‘study evaluated that the overall and complete response rate was 90% and 77% in untreated DLBCL patients who treated with PD-1 anti-body pembrolizumab and R-CHOP therapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). And the results show that PD-L1 inhibitor and R-CHOP does not increase severe toxicity, nor impede the safe delivery of 6 cycles of chemotherapy and have high efficacy[60]. In the study of Ting Wei e.t, they show that the combination with PD-1/PD-L1 inhibitor can increased the antitumor immune response in DLBCL, which showed more longer survival rite compared with the single chemotherapy drug or single PD-1/PD-L1 inhibitor[24].

**2.4 PD-1/PD-L1 antibodies combination with radiotherapy**

With the development and success of checkpoint blockade in the clinical, the combination of radiotherapy and PD-1 / PD-L1 blockade is regarded as great interest, and there are some pre-clinical evidence highlights the cooperative potential of this combination[61, 62]. For example, asparaginase/pegaspargase containing regimens combined with radiotherapy are very effectual and it is regarded as the foundation stone of localized Natural killer/T-cell lymphoma (NKTL) treatment. A retrospective study indicates that the combination of anti-PD-1 antibody with anlotinib and pegaspargase is a promising regimen “sandwich” with radiotherapy for treating localized NTKL, which is less toxicity and better tolerance[63]. What’s more, one ongoing phase I/II trial (NCT01976585) investigating local radiotherapy in combination with local ap-plication of immunostimulatory agents in patients with indolent lymphoma further support the combination of radiotherapy and PD-1 / PD-L1 blockade[64].

**2.5 PD-1/PD-L1 antibodies combination with Car-T therapy**

Car-T therapy is one type of gene therapy in which researchers use TCR or chimeric antigen receptor (CAR) to engineer T cells, therefore, it can specifically recognize tumor antigens and kill tumor cells[65]. China leads the total number of CAR-T cell therapies in the world, with two CD19-targeted CAR-T cell therapies recently approved [66, 67]. We get great success and unprecedented results in Car-T therapy in refractory/relapsed lymphoma、leukemia and myeloma[68]. While some of patients show no respond to CAR T cell therapy, even relapsing after CAR T cell therapy. Therefore, studies have reported that the application of reduced-dose PD-1 blockade therapy combined with CAR-T cell therapy has been applied to enhance anti-tumor effect in preclinical models and clinical trials, which bring a promising treatment option for relapsed/refractory lymphomas[69-71].

**3.Role of IL-17A in tumor**

Th17 cells and interleukin (IL)-17A play a significant part in the progression of tumor.

Recent studies have proved that IL-17A promotes tumor growth during early tumorigenesis, whereas in established tumors, IL-17A suppresses tumor growth by enhancing antitumor immunity[72]. In lymphomas, the most parts of studies demonstrate that IL-17A acts as a role in promoting tumor growth, so the inhibition of producing IL-17A may be an important strategy to enhance the sensitivity and therapeutic benefit of chemotherapy[73, 74]. While in another study, Xin X et. set up an adoptive immunotherapy of Th17 cells on DLBCL tumor-bearing mice, proving that IL-17 play an antitumor effect on lymphoma[75]. Therefore, the role of IL-17A in cancer remains controversial.

**3.1 Tumor-promoting functions of IL-17A**

IL-17A acts as a cancer-promoting effects role by stimulating tumor cells directly or by inducing an immunosuppressive tumor microenvironment indirectly.

IL-17A could promote angiogenesis through the VEGF pathway and CXCR-2-dependent pathway to promote tumor growth[76] [77]. In Hiromi Okuyama et. study, they find treatment with an antagonistic IL-17A antibody in mice can inhibits tumor development through elevating IFN-γ production, it indicates IL-17A play an antitumor activity through influencing IFN-γ production[78]. The work by Chang showed that the IL-17A produced by Th17 cells in the mice lung cancer model K-ras (G12D) could induce the growth of tumor by recruiting the myeloid suppressor cells[79]. Some studies revealed that IL-17A affect the nuclear factor (NF)-κB and p38 mitogen-activated protein kinases (MAPK) signaling pathway can stimulate tumor growth[80, 81]. IL-17A can increases tumor cell invasion and metastasis, also can support the survival of tumor cells at faraway organs by up-regulating ERK signaling directly [82]. IL-17A can enhance the ability of tumor growth by inducting IL-6, because the IL-6 activate oncogenic transcription factor signal transducer and activator of transcription 3 (STAT3), and up-regulate pro-survival and pro-angiogenic genes in tumors[83].

**3.2Tumor-suppressing functions of IL-17A**

The study of Ilona Kryczek show that the growth and metastasis of tumor were increased in the IL-17-deficient mice, which is related to the decreased of tumor specific interferon-gamma(+) T cells and interferon-gamma(+) natural killer cells in the tumors, showing that IL-17A may play a protective part in cancer immunity, and it can restrain tumor growth and metastasis by IFN-c producing NK and T cells[84]. The results of Martin-Orozco indicate that Th17 cells and IL-17A play a protective role through inhibiting tumors and hindering tumor development by activation of tumor-specific CD8(+) T cells[85]. In the study of Fabrice Benchetrit, their results show that IL-17A inhibited the growth rate of lymphoma J558L and mastocytoma P815, suggesting that the anti-tumor activity of IL-17 is a host-dependent mechanism involving T lymphocytes[86]. Another study revealed that IL-17A accelerated dendritic cell (DC) recruitment into the tumor tissues, thus leading CTL expansion, which is crucial for the antitumor effect[87].

**Conclusion**

In some cancer, lots of patients have got remarkable anti-tumor effects by blocking the PD-L1/PD-1 signal pathway, however, the response rates against tumors after PD-1/PD-L1 immunotherapy were limited and even some of them were completely unresponsive. Therefore, we should find another new checkpoint inhibitors to combination with PD-L1/PD-1 inhibitors for raising up its response rate in tumor, especially in lymphoma.

With a better understanding about the PD-1/PD-L1 and IL-17A in our review, we speculate that they maybe have an interaction in tumor microenvironment, which may help us to find a novel and promising immunotherapeutic target in curing lymphoma. However, this guess needs further in vitro and in vivo research, so that we can develop and implement novel ways to combat tumors.

**Declarations**

**Authors’ contributions:** The author contributed solely to the article.

**Availability of data and materials:** Not applicable.

**Financial support and sponsorship:** None.

**Conflicts of interest:** Xin Xu is a member of the Edito- rial Board of Aging Pathobiology and Therapeutics. All authors declare no conflicts of interest and were not in- volved in the journal’s review or decisions related to this manuscript.

**Ethical approval and consent to participate:** Not applicable.

**References:**

 [1]. Keir, M.E., et al., PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol, 2008. 26: p. 677-704.

 [2]. Ahmadzadeh, M., et al., Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood, 2009. 114(8): p. 1537-44.

 [3]. Kiyasu, J., et al., Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood, 2015. 126(19): p. 2193-201.

 [4]. Miyoshi, H., et al., PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. Blood, 2016. 128(10): p. 1374-81.

 [5]. Ishikawa, E., et al., Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma. J Gastroenterol, 2020. 55(1): p. 39-50.

 [6]. Ruan, J., et al., The effect of PD-1 expression on tumor-associated macrophage in T cell lymphoma. Clin Transl Oncol, 2021. 23(6): p. 1134-1141.

 [7]. Jiang, Y., et al., PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother, 2019. 15(5): p. 1111-1122.

 [8]. Iwakura, Y., et al., Functional specialization of interleukin-17 family members. Immunity, 2011. 34(2): p. 149-62.

 [9]. Chung, S.H., X.Q. Ye and Y. Iwakura, Interleukin-17 family members in health and disease. Int Immunol, 2021. 33(12): p. 723-729.

[10]. McGeachy, M.J., D.J. Cua and S.L. Gaffen, The IL-17 Family of Cytokines in Health and Disease. Immunity, 2019. 50(4): p. 892-906.

[11]. Ruiz, D.M.J., et al., Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmun Rev, 2020. 19(1): p. 102429.

[12]. Zhong, W., et al., Human bone marrow-derived mesenchymal stem cells promote the growth and drug-resistance of diffuse large B-cell lymphoma by secreting IL-6 and elevating IL-17A levels. J Exp Clin Cancer Res, 2019. 38(1): p. 73.

[13]. Zhong, W. and Q. Li, Rituximab or irradiation promotes IL-17 secretion and thereby induces resistance to rituximab or irradiation. Cell Mol Immunol, 2017. 14(12): p. 1020-1022.

[14]. Zhong, W., et al., Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma. Int J Oncol, 2018. 52(5): p. 1528-1538.

[15]. Ma, Y.F., et al., Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer. Oncotarget, 2017. 8(5): p. 7614-7624.

[16]. Shuai, C., et al., Estrogen Receptor Downregulates Expression of PD-1/PD-L1 and Infiltration of CD8(+) T Cells by Inhibiting IL-17 Signaling Transduction in Breast Cancer. Front Oncol, 2020. 10: p. 582863.

[17]. Stein, S., et al., IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression. J Hepatol, 2021. 74(4): p. 919-930.

[18]. Wang, X., et al., Inflammatory cytokines IL-17 and TNF-alpha up-regulate PD-L1 expression in human prostate and colon cancer cells. Immunol Lett, 2017. 184: p. 7-14.

[19]. Zhang, W., et al., B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy? Front Oncol, 2021. 11: p. 647526.

[20]. Andorsky, D.J., et al., Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res, 2011. 17(13): p. 4232-44.

[21]. Yamamoto, R., et al., B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma. Cancer Sci, 2009. 100(11): p. 2093-100.

[22]. Lv, K., et al., Selection of new immunotherapy targets for NK/T cell lymphoma. Am J Transl Res, 2020. 12(11): p. 7034-7047.

[23]. Horlad, H., et al., An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma. Cancer Sci, 2016. 107(11): p. 1696-1704.

[24]. Wei, T., et al., Vincristine upregulates PD-L1 and increases the efficacy of PD-L1 blockade therapy in diffuse large B-cell lymphoma. J Cancer Res Clin Oncol, 2021. 147(3): p. 691-701.

[25]. Song, T.L., et al., Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood, 2018. 132(11): p. 1146-1158.

[26]. Jelinek, T., et al., PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology, 2017. 152(3): p. 357-371.

[27]. Green, M.R., et al., Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood, 2010. 116(17): p. 3268-77.

[28]. Green, M.R., et al., Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood, 2010. 116(17): p. 3268-77.

[29]. Wang, Y., et al., Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer J, 2019. 9(9): p. 73.

[30]. Duffield, A.S., et al., Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy. Blood Adv, 2017. 1(17): p. 1324-1334.

[31]. Nagasaki, J., et al., The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma. Blood Adv, 2020. 4(17): p. 4069-4082.

[32]. Ansell, S.M., et al., PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med, 2015. 372(4): p. 311-9.

[33]. Younes, A., et al., Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol, 2016. 17(9): p. 1283-94.

[34]. Armand, P., et al., Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol, 2019. 37(34): p. 3291-3299.

[35]. Ding, W., et al., Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood, 2017. 129(26): p. 3419-3427.

[36]. Chen, R., et al., Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood, 2019. 134(14): p. 1144-1153.

[37]. Shi, Y., et al., Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). J Hematol Oncol, 2021. 14(1): p. 12.

[38]. Song, Y., et al., A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. Clin Cancer Res, 2019. 25(24): p. 7363-7369.

[39]. Chen, J., et al., Tislelizumab for the treatment of classical Hodgkin's lymphoma. Drugs Today (Barc), 2020. 56(12): p. 781-785.

[40]. Tao, R., et al., Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4). Signal Transduct Target Ther, 2021. 6(1): p. 365.

[41]. Kim, S.J., et al., Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study. Blood, 2020. 136(24): p. 2754-2763.

[42]. Geoerger, B., et al., Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study. Lancet Oncol, 2020. 21(1): p. 134-144.

[43]. Armand, P., et al., Programmed Death-1 Blockade with Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol, 2016. 34(31): p. 3733-3739.

[44]. Ansell, S.M., et al., PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med, 2015. 372(4): p. 311-9.

[45]. Xu-Monette, Z.Y., J. Zhou and K.H. Young, PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood, 2018. 131(1): p. 68-83.

[46]. Xie, W., et al., PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas. Curr Hematol Malig Rep, 2020. 15(4): p. 372-381.

[47]. Goodman, A., S.P. Patel and R. Kurzrock, PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol, 2017. 14(4): p. 203-220.

[48]. Armand, P., et al., Programmed Death-1 Blockade with Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol, 2016. 34(31): p. 3733-3739.

[49]. Chen, R., et al., Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol, 2017. 35(19): p. 2125-2132.

[50]. Chen, L. and X. Han, Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest, 2015. 125(9): p. 3384-91.

[51]. Haanen, J.B. and C. Robert, Immune Checkpoint Inhibitors. Prog Tumor Res, 2015. 42: p. 55-66.

[52]. Larkin, J., et al., Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med, 2015. 373(1): p. 23-34.

[53]. Tobin, J., et al., PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma. Cells, 2021. 10(5).

[54]. Chen, B.J., et al., The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma. Oncotarget, 2019. 10(21): p. 2030-2040.

[55]. Lee, Y.H., et al., PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. Mol Ther, 2022. 30(2): p. 579-592.

[56]. Tan, J., et al., Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML. Biomark Res, 2020. 8: p. 6.

[57]. Ge, Z., et al., TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. Front Immunol, 2021. 12: p. 699895.

[58]. Josefsson, S.E., et al., TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma. Cancer Immunol Res, 2019. 7(3): p. 355-362.

[59]. Zhang, R., et al., Synergistic effect of programmed death-1 inhibitor and programmed death-1 ligand-1 inhibitor combined with chemotherapeutic drugs on DLBCL cell lines in vitro and in vivo. Am J Cancer Res, 2020. 10(9): p. 2800-2812.

[60]. Smith, S.D., et al., Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy. Br J Haematol, 2020. 189(6): p. 1119-1126.

[61]. Zhuang, H., Abscopal effect of stereotactic radiotherapy combined with anti-PD-1/PD-L1 immunotherapy: Mechanisms, clinical efficacy, and issues. Cancer Commun (Lond), 2020. 40(12): p. 649-654.

[62]. Park, S.S., et al., PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Cancer Immunol Res, 2015. 3(6): p. 610-9.

[63]. Sun, P., et al., Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase "Sandwich" With Radiotherapy in Localized Natural Killer/T Cell Lymphoma. Front Immunol, 2022. 13: p. 766200.

[64]. Hammerich, L., et al., Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med, 2019. 25(5): p. 814-824.

[65]. Porter, D.L., et al., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med, 2011. 365(8): p. 725-33.

[66]. First-Ever CAR T-cell Therapy Approved in U.S. Cancer Discov, 2017. 7(10): p. OF1.

[67]. Golubovskaya, V., CAR-T Cell Therapy: From the Bench to the Bedside. Cancers (Basel), 2017. 9(11).

[68]. Tang, J., A. Shalabi and V.M. Hubbard-Lucey, Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol, 2018. 29(1): p. 84-91.

[69]. Zhang, R., et al., Effect and changes in PD1 expression of CD19 CART cells from T cells highly expressing PD1 combined with reduceddose PD1 inhibitor. Oncol Rep, 2019. 41(6): p. 3455-3463.

[70]. Song, W. and M. Zhang, Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. Clin Immunol, 2020. 214: p. 108382.

[71]. Wang, J., et al., CAR-T 19 combined with reduced-dose PD-1 blockade therapy for treatment of refractory follicular lymphoma: A case report. Oncol Lett, 2019. 18(5): p. 4415-4420.

[72]. Vitiello, G.A. and G. Miller, Targeting the interleukin-17 immune axis for cancer immunotherapy. J Exp Med, 2020. 217(1).

[73]. Guo, H.Z., et al., Leukemic IL-17RB signaling regulates leukemic survival and chemoresistance. FASEB J, 2019. 33(8): p. 9565-9576.

[74]. Zhong, W., et al., Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma. Int J Oncol, 2018. 52(5): p. 1528-1538.

[75]. XuXin, et al., The effect of Th17 cell adoptive immunotherapy on tumor growth in mice bearing diffuse large B-cell lymphoma. Journal of Leukemia and Lymphoma, 2015. 24(12): P722-725.

[76]. Numasaki, M., et al., IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol, 2005. 175(9): p. 6177-89.

[77]. Nicola, S., et al., IL-17 Promotes Nitric Oxide Production in Non-Small-Cell Lung Cancer. J Clin Med, 2021. 10(19).

[78]. Okuyama, H., et al., Spirulina lipopolysaccharides inhibit tumor growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to interferon-gamma. Oncol Rep, 2017. 37(2): p. 684-694.

[79]. Chang, S.H., et al., T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci U S A, 2014. 111(15): p. 5664-9.

[80]. Xiang, T., et al., Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer. Oncogene, 2015. 34(2): p. 165-76.

[81]. Cochaud, S., et al., IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Sci Rep, 2013. 3: p. 3456.

[82]. Wu, H.H., et al., Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines. J Exp Med, 2015. 212(3): p. 333-49.

[83]. Tartour, E., et al., Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res, 1999. 59(15): p. 3698-704.

[84]. Kryczek, I., et al., Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood, 2009. 114(2): p. 357-9.

[85]. Martin-Orozco, N., et al., T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity, 2009. 31(5): p. 787-98.

[86]. Benchetrit, F., et al., Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood, 2002. 99(6): p. 2114-21.

[87]. Martin-Orozco, N., et al., T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity, 2009. 31(5): p. 787-98.